| ||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
Since the level of 7-KETO is directly related to the level of DHEA in the body,7 people with lower DHEA levels likely have low 7-KETO levels as well. Low DHEA levels are primarily associated with aging.
A safety study in humans has shown that 7-KETO did not raise oestrogen or testosterone levels or produce any other negative effects at levels up to 200 mg per day for eight weeks.8 Short-term animal studies also revealed no adverse effects with large amounts of 7-KETO.9 10 11 However, the long-term safety of 7-KETO for humans has not been demonstrated, and, because it is chemically related to steroid hormones, the potential for adverse effects must be considered. In addition, the increase in T3 levels resulting from taking 7-KETO could, in theory, produce adverse effects on the heart or promote bone loss. For these reasons, people wishing to take 7-KETO, particularly those who have a thyroid disorder or are taking thyroid hormone, should consult a physician.
At the time of writing, there were no well-known drug interactions with 7-KETO.
1. Lardy H, Kneer N, Wei Y, et al. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 1998;63:158-65.
2. Shi J, Lardy H. 3β-Hydroxyandrost-5-ene-7,17-dione (7-keto-DHEA) improves memory in mice. FASEB J 1998;12:A4427.
3. Reich IL, Lardy H, Wei Y, et al. Ergosteroids III. Syntheses and biological activity of seco-steroids related to dehydroepiandrosterone. Steroids 1998;63:542-53.
4. Lardy H, Kneer N, Wei Y, et al. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 1998;63:158-65.
5. Bobyleva V, Bellei M, Kneer N, Lardy H. The effects of the ergosteroid 7-oxo-dehydroepiandrosterone on mitochondrial membrane potential: possible relationship to thermogenesis. Arch Biochem Biophys 1997;341:122-8.
6. Colker CM, Torina GC, Swain MA, Kalman DS. Double-blind study evaluating the effects of exercise plus 3-acetyl-7-oxo-dehydroepiandrosterone on body composition and the endocrine system in overweight adults. J Exercise Physiology Online 1999;2(4).
7. Lardy H, Kneer N, Wei Y, et al. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 1998;63:158–65.
8. Davidson MH, Weeks CE, Lardy H, et al. Safety and endocrine effects of 3-acetyl-7-oxo DHEA (7-keto DHEA). FASEB J 1998;12:A4429.
9. Lardy H, Henwood SM, Weeks CE. An acute oral gavage study of 3beta-acetoxyandrost- 5-ene-7,17-dione (7-oxo-DHEA-acetate) in rats. Biochem Biophys Res Commun 1999;254:120–3.
10. Henwood SM, Weeks CE, Lardy H. An escalating dose oral gavage study of 3beta-acetoxyandrost-5-ene-7, 17-dione (7-oxo-DHEA-acetate) in rhesus monkeys. Biochem Biophys Res Commun 1999;254:124–6.
11. Weeks C, Lardy H, Henwood S. Preclinical toxicology evaluation of 3-acetyl-7-oxo-dehydroepiandrosterone (7-keto DHEA). FASEB J 1998;12:A4428.
| |||||||